Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).

von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Edler L, Munzinger J, Efferth T, Schneeweiss A, Strowitzki T.

Breast Cancer Res Treat. 2017 Jul;164(2):359-369. doi: 10.1007/s10549-017-4261-1. Epub 2017 Apr 24.


Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry].

Wienbergen H, Pfister O, Hochadel M, Michel S, Bruder O, Remppis BA, Maeder MT, Strasser R, von Scheidt W, Pauschinger M, Senges J, Hambrecht R; RAID-HF (Registry Analysis of Iron Deficiency–Heart Failure) REGISTRY Study Group.

Am J Cardiol. 2016 Dec 15;118(12):1875-1880. doi: 10.1016/j.amjcard.2016.08.081. Epub 2016 Sep 15.


[Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group "heart-kidney" of the German Cardiac Society and the German Society of Nephrology].

Schwenger V, Remppis BA, Westenfeld R, Weinreich T, Brunkhorst R, Schieren G, Krumme B, Haller H, Schmieder R, Schlieper G, Frye B, Hoppe UC, Hoyer J, Keller T, Blumenstein M, Schunkert H, Mahfoud F, Rump LC.

Dtsch Med Wochenschr. 2014 Feb;139(7):e1-8. doi: 10.1055/s-0033-1360037. Epub 2014 Feb 4. Review. German.


Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators.

Eur Heart J. 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/eht342. Epub 2013 Sep 2.


Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.


The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders.

Frankenstein L, Zugck C, Nelles M, Schellberg D, Katus HA, Remppis BA.

Eur J Heart Fail. 2009 Dec;11(12):1189-94. doi: 10.1093/eurjhf/hfp150. Epub 2009 Nov 3.


Validity, prognostic value and optimal cutoff of respiratory muscle strength in patients with chronic heart failure changes with beta-blocker treatment.

Frankenstein L, Nelles M, Meyer FJ, Sigg C, Schellberg D, Remppis BA, Katus HA, Zugck C.

Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):424-9. doi: 10.1097/HJR.0b013e3283030a7e.


Supplemental Content

Loading ...
Support Center